{
    "clinical_study": {
        "@rank": "11519", 
        "acronym": "XANTUS-EL", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "This international study is a prospective noninterventional observational cohort study of\n      patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine\n      treatment conditions to prevent stroke or non-central nervous system systemic embolism.\n      Patients will be followed up for 1 year or until 30 days after end of rivaroxaban therapy in\n      case of therapy was discontinued earlier than 12 months. Serious adverse events will be\n      followed up adequately. Laboratory values (e.g., Hb, HCT, haemoccult) should be documented\n      for each point in time they were measured."
        }, 
        "brief_title": "Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Stroke"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female and male patients \u2265 18 years of age with a diagnosis of non-valvular atrial\n             fibrillation who start treatment with rivaroxaban to prevent stroke or non-CNS\n             systemic embolism, and who consent to participate in the study.\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under\n        routine treatment conditions to prevent stroke or noncentral nervous system systemic\n        embolism."
            }
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01800006", 
            "org_study_id": "16691", 
            "secondary_id": "XA1206"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.", 
            "intervention_name": "Rivaroxaban (Xarelto, BAY59-7939)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Atrial Fibrillation", 
            "Observation", 
            "Stroke", 
            "Embolism"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Algeria"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Argentina"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Azerbaijan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Bahrain"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Chile"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Colombia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Ecuador"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Egypt"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Georgia"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ManyLocations", 
                        "country": "Jordan"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Kazakhstan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Kazakhstan"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Kenya"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Kuwait"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ManyLocations", 
                        "country": "Lebanon"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Mexico"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Morocco"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Peru"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Qatar"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Russian Federation"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ManyLocations", 
                        "country": "Saudi Arabia"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Ukraine"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "United Arab Emirates"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Uruguay"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Many Locations", 
                        "country": "Venezuela"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Algeria", 
                "Argentina", 
                "Azerbaijan", 
                "Bahrain", 
                "Chile", 
                "Colombia", 
                "Ecuador", 
                "Egypt", 
                "Georgia", 
                "Jordan", 
                "Kazakhstan", 
                "Kenya", 
                "Kuwait", 
                "Lebanon", 
                "Mexico", 
                "Morocco", 
                "Peru", 
                "Qatar", 
                "Russian Federation", 
                "Saudi Arabia", 
                "Ukraine", 
                "United Arab Emirates", 
                "Uruguay", 
                "Venezuela"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "XANTUS-EL, Xarelto\u00ae on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A Noninterventional Study", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica", 
                "Argentina: Human Research Bioethics Committee", 
                "Belarus: Ministry of Health", 
                "Chile: Comisi\u00f3n Nacional de Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Ecuador: Public Health Ministry", 
                "Ecuador: Ethical Committee", 
                "Egypt: Institutional Review Board", 
                "Jordan: Ethical Committee", 
                "Kazakhstan: Ethical Commission", 
                "Kenya: Ethical Review Committee", 
                "Kenya: Institutional Review Board", 
                "Kenya: Ministry of Health", 
                "Lebanon: Ministry of Public Health", 
                "Lebanon: Institutional Review Board", 
                "Mexico: Ministry of Health", 
                "Peru: Ministry of Health", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Saudi Arabia: Ministry of Health", 
                "Ukraine: Ministry of Health", 
                "United Arab Emirates: Drug Control Department - Medicines and Pharmacy Control - Ministry of Health", 
                "Venezuela: Ministry of Health and Social Development"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Adjudicated major bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"
            }, 
            {
                "measure": "Safety variables will be summarized using descriptivestatistics based on adverse events collection", 
                "safety_issue": "Yes", 
                "time_frame": "after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01800006"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "All cause mortality", 
                "safety_issue": "Yes", 
                "time_frame": "after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"
            }, 
            {
                "measure": "Adjudicated symptomatic thromboembolic events", 
                "safety_issue": "Yes", 
                "time_frame": "after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}